Summary & Overview
CPT 0383U: Tyrosinemia FollowUp Panel, SelfCollect Blood Spot
CPT code 0383U is a Proprietary Laboratory Analyses (PLA) code that describes the Tyrosinemia FollowUp Panel, SelfCollect, Blood Spot, performed by Mayo Clinic. The panel measures tyrosine, phenylalanine, methionine, succinylacetone, and nitisinone in a patient-collected dried blood spot using LC–MS/MS. As a PLA code, 0383U applies to a single manufacturer or laboratory test and signals proprietary assay reporting and billing.
Nationally, this code matters for follow-up metabolic monitoring of patients with tyrosinemia or those on nitisinone therapy, and for payers and providers managing home-collected laboratory workflows. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Information on coverage policies and reimbursement benchmarks for PLA codes is important for laboratory billing, prior authorization processes, and patient access to at-home monitoring.
Readers will learn the clinical purpose of the test, the typical service and site of service, payer coverage scope, and where to find policy and billing considerations specific to PLA-coded assays. Data not available in the input: associated taxonomies, ICD-10 diagnoses, related codes, and detailed payer policy specifics.
Billing Code Overview
CPT code 0383U is a Proprietary Laboratory Analyses (PLA) code for the Tyrosinemia FollowUp Panel, SelfCollect, Blood Spot, performed by Mayo Clinic. The test evaluates a patient-collected blood spot specimen for levels of tyrosine, phenylalanine, methionine, succinylacetone, and nitisinone using liquid chromatography with tandem mass spectrometry (LC–MS/MS).
Service Type: Laboratory — specialty biochemical genetic/metabolic monitoring
Typical Site of Service: Patient-collected at home with specimen returned to the laboratory; testing performed in a clinical laboratory (Mayo Clinic)
Clinical & Coding Specifications
Clinical Context
A patient with hereditary tyrosinemia or a person receiving nitisinone therapy collects a blood spot specimen at home using the manufacturer-supplied self-collection kit and returns the sample to Mayo Clinic for analysis. The test, billed with 0383U, measures tyrosine, phenylalanine, methionine, succinylacetone, and nitisinone concentrations using LC–MS/MS to monitor biochemical control and drug levels. Typical workflow: the clinician orders the Tyrosinemia FollowUp Panel for outpatient monitoring or post-discharge follow-up, the laboratory provides the self-collection kit and instructions, the patient collects a dried blood spot (DBS) and ships it to Mayo Clinic, the laboratory performs LC–MS/MS analysis, generates a report, and the ordering clinician reviews results to guide metabolic management and nitisinone dosing adjustments. Typical site of service is outpatient/home collection with laboratory analysis at a reference diagnostic laboratory. Typical patient scenarios include routine follow-up of diagnosed hereditary tyrosinemia type I on nitisinone therapy, assessment of suspected drug nonadherence or subtherapeutic nitisinone levels, and monitoring after a change in therapy or clinical status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — standard billing | Use when no special billing modifiers apply to this PLA test. |